Licence deal
Isogenica Ltd has entered into a research and licence agreement with Wyeth Pharmaceuticals to use its peptide display technology to select therapeutic peptide candidates to an unspecified number of Wyeth targets.
The Cambridge-based company will receive research fees and milestone and royalty payments for the development and commercialisation of any products resulting from the collaboration.
Isogenica’s display technology provides a means of rapidly identifying peptides that bind with high affinity and specificity to any given molecular target. The technology can also be used for enhancing the performance of peptides in vivo.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
